BRD4-mediated repression of p53 is a target for combination therapy in AML

BRD4-mediated repression of p53 is a target for combination therapy in AML

MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.

Bibliographic Details
Main Authors:	Anne-Louise Latif, Ashley Newcombe, Sha Li, Kathryn Gilroy, Neil A. Robertson, Xue Lei, Helen J. S. Stewart, John Cole, Maria Terradas Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Joana Campos, Kristina Kirschner, Andrew Davis, Jonathan Lopez, Jun-ichi Sakamaki, Jennifer P. Morton, Kevin M. Ryan, Stephen W. G. Tait, Sheela A. Abraham, Tessa Holyoake, Brian Higgins, Xu Huang, Karen Blyth, Mhairi Copland, Timothy J. T. Chevassut, Karen Keeshan, Peter D. Adams
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-01-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-020-20378-8

Internet

https://doi.org/10.1038/s41467-020-20378-8